Pharmafile Logo
Pharmafocus logo
Advanced Search

Genmab

Showing 15 posts of 32 posts found.

cancer

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …

News
clinical_trial_4

Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration

June 2, 2016
Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III

Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …

News
clinical_trial_3

Darzalex meets endpoint in late-stage multiple myeloma trial

May 19, 2016
Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial

Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …

News
legal

Janssen and Genmab sued for patent infringement in US

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement

German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).

News
cancer_cells

Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours

March 22, 2016
Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour

Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …

News
arzerra_novartis

Novartis seeks expanded Arzerra use in US

March 11, 2016
Research and Development Arzerra, CLL, FDA, Genmab, Novartis

Novartis has submitted a supplemental Biologics License Application (sBLA) to the US FDA for the use of Arzerra (ofatumumab) in …

News
genmab

Genmab Darzalex success triggers second milestone payment

March 10, 2016
Research and Development, Sales and Marketing Genmab, Janssen, daratumumab, darzalex, follicular lymphoma

Genmab says it has reached a $5 million milestone in its daratumumab collaboration with Janssen as a result of success …

News
Arzerra

Arzerra approved by US FDA for leukaemia

January 20, 2016
Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application

The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …

News
Arzerra

Genmab pulls plug on Phase III Arzerra trial

November 24, 2015
Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure

Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …

News
GSK logo

GSK’s Arzerra fails in lymphoma

May 21, 2014
Research and Development, Sales and Marketing Arzerra, GSK, Genmab, non-Hodgkin lymphoma

News
Arzerra image

EMA gets first line Arzerra submission

October 7, 2013
Sales and Marketing Arzerra, GSK, Genmab, blood cancer

GlaxoSmithKline and Genmab have submitted their blood cancer drug Arzerra to the European Medicines Agency (EMA) in a first line …

News
gsk_hedge

GSK/Genmab leukaemia drug joins FDA speed lane

September 16, 2013
Research and Development, Sales and Marketing Arzerra, GSK, Genmab, Levact, MabThera, chronic lymphocytic leukaemia

News

J&J buys into Genmab cancer drug

August 31, 2012
Sales and Marketing Cancer, Genmab, Janssen Cilag, Janssen-Cilag, Johnson & Johnson, multiple myeloma

Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen …

News
GSK image

GSK settles cancer patent dispute

March 28, 2012
Research and Development, Sales and Marketing GSK, Genmab, Roche, ofatumumab, patents

GlaxoSmithKline has settled a long-running patent dispute over its cancer treatment ofatumumab.  The US patents, which relate to recombinant antibody …

News

GSK switches to subcutaneous route for antibody

September 16, 2010
Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab

GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025